A meta-analysis found GLP-1s cut cardiovascular events by a fifth in people without diabetes
A systematic review and meta-analysis of 16 randomised trials covering 23,467 participants with obesity but not diabetes, over a median 68 weeks, reported a 20 per cent reduction in major adverse cardiovascular events. Effects were strongest for stroke, then heart attack, then hospitalisation for heart failure, alongside reductions in blood pressure, triglycerides and inflammatory markers. Mediation analysis suggested that between 35 and 55 per cent of the cardiovascular benefit was independent of weight loss itself.
What this actually means
A meta-analysis pools many trials, so it carries more weight than any single one. This is among the stronger pieces of evidence in the whole field.
The genuinely interesting finding is the last one. Between a third and a half of the heart benefit did not come from losing weight. Something else is happening, probably involving inflammation and blood vessel function directly. That reframes these drugs as metabolic medicines that happen to cause weight loss, rather than weight-loss drugs that happen to help hearts.
Two cautions. This is people with obesity at raised risk, not the general population, so do not read it as a heart pill for anyone. And 68 weeks is a median follow-up, not a lifetime, so this tells you about the first year or two and nothing about the next twenty.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.